PURPOSE: The ruthenium complex salt indazolium trans-[tetrachlorobisindazole-ruthenate(III)] (KP1019) and the analogous sodium salt KP1339 are effective tumor-inhibiting drugs in experimental therapy of autochthonous colorectal carcinomas in rats. This paper examines the cell biological mechanisms underlying their antineoplastic effects. METHODS: Colorectal tumor cell lines were used to analyze uptake of the ruthenium(III) complexes into the cells and the mechanism as well as the efficacy of their cytotoxic effects. RESULTS: KP1019 and KP1339 are efficiently taken up into the cells: 100 microM ruthenium(III) complex in the growth medium led to the uptake of 120-160 ng ruthenium per 10(6) cells within 30 min. Uptake of KP418 was tenfold lower correlating with its lower cytotoxic efficiency. KP1019 and KP1339 induced apoptosis in SW480 and HT29 cells predominantly by the intrinsic mitochondrial pathway as indicated by loss of mitochondrial membrane potential. Correspondingly sensitivity of the cells paralleled expression of bcl(2) while it was only slightly affected by mutations in Ki-ras. CONCLUSIONS: Our data demonstrate that trans-[tetrachlorobisindazole-ruthenate(III)] complex salts are promising candidate drugs in the second-line treatment of colorectal cancers resistant to other cytostatic drugs and has been introduced into phase I clinical trials.
PURPOSE: The ruthenium complex salt indazoliumtrans-[tetrachlorobisindazole-ruthenate(III)] (KP1019) and the analogous sodium salt KP1339 are effective tumor-inhibiting drugs in experimental therapy of autochthonous colorectal carcinomas in rats. This paper examines the cell biological mechanisms underlying their antineoplastic effects. METHODS:Colorectal tumor cell lines were used to analyze uptake of the ruthenium(III) complexes into the cells and the mechanism as well as the efficacy of their cytotoxic effects. RESULTS: KP1019 and KP1339 are efficiently taken up into the cells: 100 microM ruthenium(III) complex in the growth medium led to the uptake of 120-160 ng ruthenium per 10(6) cells within 30 min. Uptake of KP418 was tenfold lower correlating with its lower cytotoxic efficiency. KP1019 and KP1339 induced apoptosis in SW480 and HT29 cells predominantly by the intrinsic mitochondrial pathway as indicated by loss of mitochondrial membrane potential. Correspondingly sensitivity of the cells paralleled expression of bcl(2) while it was only slightly affected by mutations in Ki-ras. CONCLUSIONS: Our data demonstrate that trans-[tetrachlorobisindazole-ruthenate(III)] complex salts are promising candidate drugs in the second-line treatment of colorectal cancers resistant to other cytostatic drugs and has been introduced into phase I clinical trials.
Authors: K C Peng; F Cluzeaud; M Bens; J P Duong Van Huyen; M A Wioland; R Lacave; A Vandewalle Journal: J Histochem Cytochem Date: 1999-06 Impact factor: 2.479
Authors: M Tomonaga; M Oka; F Narasaki; M Fukuda; R Nakano; H Takatani; K Ikeda; K Terashi; I Matsuo; H Soda; K H Cowan; S Kohno Journal: Jpn J Cancer Res Date: 1996-12
Authors: Alexander E Egger; Christina Rappel; Michael A Jakupec; Christian G Hartinger; Petra Heffeter; Bernhard K Keppler Journal: J Anal At Spectrom Date: 2009-01 Impact factor: 4.023
Authors: Floyd A Beckford; Michael Shaloski; Gabriel Leblanc; Jeffrey Thessing; Lesley C Lewis-Alleyne; Alvin A Holder; Liya Li; Navindra P Seeram Journal: Dalton Trans Date: 2009-09-28 Impact factor: 4.390
Authors: Virtudes Moreno; Julia Lorenzo; Francesc X Aviles; M Helena Garcia; João P Ribeiro; Tânia S Morais; Pedro Florindo; M Paula Robalo Journal: Bioinorg Chem Appl Date: 2010-06-20 Impact factor: 7.778
Authors: Orsolya Dömötör; Christian G Hartinger; Anna K Bytzek; Tamás Kiss; Bernhard K Keppler; Eva A Enyedy Journal: J Biol Inorg Chem Date: 2012-10-18 Impact factor: 3.358